On January 30, 2023, BMO Capital initiated coverage of BioMarin Pharmaceutical with a Market Perform recommendation.
Analyst Price Forecast Suggests 7.20% Upside
As of January 31, 2023, the average one-year price target for BioMarin Pharmaceutical is $122.96. The forecasts range from a low of $83.83 to a high of $210.00. The average price target represents an increase of 7.20% from its latest reported closing price of $114.70.
The projected annual revenue for BioMarin Pharmaceutical is $2,613MM, an increase of 30.11%. The projected annual EPS is $1.47, an increase of 222.58%.
What are large shareholders doing?
Primecap Management holds 17,625,505 shares representing…